The presence of communication between the emissary veins from the corpora cavernosa and the circum¯ex veins draining the corpus spongiosum makes it possible for the transfer of alprostadil (prostaglandin E1) in MUSE from the spongiosal compartment to the cavernosal compartment of the penis after its absorption through the urethral mucosa. This leads to engorgement and tumescence of the corpus spongiosum as well as the corpora cavernosa. Lack of tumescence of the glans penis and poor penile girth can be a cause for disappointment and frustration in patients following penile prosthetic surgery. MUSE was used successfully in a patient with a Dyna¯ex penile prosthesis to enhance the tumescence of the glans penis. It will be a useful adjunct for patients in similar circumstances.
Introduction
Although increased penile tumescence during sexual activity has been noted by impotent patients with penile prostheses, in most instances this could not be con®rmed by objective testing. 1 In the study by Fallon and Ghanem, only 21% of their patients with penile prostheses reported added tumescence in the glans penis and 38% reported added tumescence in the penile shaft. 2 Fifty-two percent of the patients studied by Montorsi et al who had erectile dysfunction associated with Peyronie's disease, and 60% of the patients' partners, were dissatis®ed with their penile prostheses, citing poor penile girth as one of the reasons. 3 Keogh and Earle described the injection of prostaglandin E1 and phentolamine into the rim of cavernosal tissue surrounding the penile prosthesis to increase the penile girth of a patient who complained that it was inadequate. 4 However, intracavernosal injections of vasoactive agents lead primarily to increased tumescence of the corpora cavernosa. These injections may be technically dif®cult in the presence of an implanted penile prosthesis. Lack of tumescence of the glans penis, in particular, has been one of the shortcomings of penile prosthetic surgery.
This report records the ef®cacy of transurethral alprostadil (prostaglandin E1), commercially marketed as MUSE (Vivus), in enhancing tumescence of the glans penis in a patient with penile prosthesis.
Case report
In June 1987, a man aged 62 y presented with decreased libido and erectile dysfunction. There were no signi®cant abnormal clinical ®ndings. A blood test showed eugonadotropic partial androgen de®ciency. He was given monthly injections of testosterone (Sustanon, Organon), and intracavernosal papaverine injection therapy was commenced. However, the erectile response to increasing doses of papaverine was inadequate. He was subsequently seen by a urologist and implant surgery was performed using a Dyna¯ex penile prosthesis.
At subsequent review, the patient expressed disappointment and frustration with the prosthesis because of lack of fullness in the glans penis.
On 16 March 1999, treatment with transurethral alprostadil (MUSE) was undertaken, using a dose of 500 mcg. This resulted 20 min later in satisfactory tumescence of the glans penis and fullness of the penile shaft without any side effect.
to ®lling of the corpus spongiosum and of the deep dorsal and circum¯ex veins which drain these tissues. 5 Numerous emissary veins communicating between the dorsolateral surfaces of the corpora cavernosa and the circum¯ex veins enable the ®lling of the cavernosal tissues. 6 MUSE provides a novel delivery system which permits the intraurethral administration and absorption of alprostadil through the urethral mucosa for transfer into the corpora cavernosa via the corpus spongiosum. The resultant smooth muscle relaxation and vasodilatation lead to engorgement and tumescence of the corpus spongiosum, of which the glans penis is a part, as well as the corpora cavernosa.
Our report con®rms a satisfactory result from the use of MUSE for its effect on spongiosal tissue.
MUSE will therefore be a useful adjunct in the management of patients with penile prostheses and will help enhance tumescence of the glans penis as well as improve penile girth in these patients without the hazards of intracavernosal injections.
